non-small cell lung cancer
HUTCHMED completes enrolment in phase 3 trial for lung cancer
August 21, 2025Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
July 4, 2025Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
Combination first-in-line treatment approved for patients with non-small cell lung cancer
January 23, 2025Research and Development J&J Innovative Medicine, Oncology, approval, non-small cell lung cancer
Johnson & Johnson Innovative Medicine have announced that the European Commission (EC) has approved a marketing authorisation for the combination …
NDA in China receives priority review status for lung cancer treatment
January 3, 2025Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
August 27, 2024Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation
July 29, 2024Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer
Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer
April 12, 2019Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …
European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer
April 4, 2019Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …
AZ to rework ongoing immuno-oncology trials to “enhance options”
January 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, non-small cell lung cancer
Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has …
Personalised medicine to drive global lung cancer market to 2020
November 29, 2016Manufacturing and Production, Sales and Marketing Technavio, lung cancer, non-small cell lung cancer
According to a new report from Technavio, the global lung cancer therapeutics market is projected to grow at more than …
Non-small cell lung cancer market to hit $26bn by 2025
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GlobalData, non-small cell lung cancer
New research from GlobalData has indicated that the non-small cell lung cancer (NSCLC) market will rise in value by over …
FDA to review MSD’s Keytruda as a first-line lung cancer treatment
September 7, 2016Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo
The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …
Pfizer nabs EU approval for Xalkori for certain lung cancers
August 31, 2016Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer
The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
AstraZeneca’s Tagrisso gets EU lung cancer sign-off
February 4, 2016Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib
The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …
